MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Blueprint Medicines Corp

Closed

SectorHealthcare

86.8 -3.53

Overview

Share price change

24h

Current

Min

85.9

Max

89.97

Key metrics

By Trading Economics

Income

6.3M

-50M

Sales

18M

146M

EPS

-0.79

Profit margin

-34.131

Employees

649

EBITDA

6.3M

-27M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+44.43% upside

Dividends

By Dow Jones

Next Earnings

1 May 2025

Market Stats

By TradingEconomics

Market Cap

5.7B

Previous open

90.33

Previous close

86.8

News Sentiment

By Acuity

67%

33%

346 / 386 Healthcare

Technical Score

By Trading Central

Confidence

Bearish Evidence

Blueprint Medicines Corp Chart

Past performance is not a reliable indicator of future results.

Related News

3 Apr 2025, 23:04 UTC

Top News

JPMorgan Raises Risk of U.S., Global Recession to 60%

3 Apr 2025, 22:40 UTC

Major Market Movers

Aldeyra Shares Fall on FDA Complete Response Letter for Dry Eye Disease Drug

3 Apr 2025, 22:18 UTC

Acquisitions, Mergers, Takeovers

Quantum Corp. Gets Strategic Investment, Names New Financial Chief

3 Apr 2025, 18:51 UTC

Acquisitions, Mergers, Takeovers

Capital One, Discover Merger Clears Regulatory Hurdle, Sources Tell The New York Times

3 Apr 2025, 23:43 UTC

Market Talk

Gold Steady, Supported by Potential Safe-Haven Demand -- Market Talk

3 Apr 2025, 23:41 UTC

Market Talk

Nikkei May Fall as U.S. Tariffs Raise Concerns About Global Growth -- Market Talk

3 Apr 2025, 22:22 UTC

Acquisitions, Mergers, Takeovers

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3 Apr 2025, 22:21 UTC

Acquisitions, Mergers, Takeovers

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3 Apr 2025, 21:43 UTC

Top News
Earnings

The Day Trump's Tariffs Shook Wall Street and Corporate America -- 5th Update

3 Apr 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

3 Apr 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3 Apr 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

3 Apr 2025, 20:43 UTC

Market Talk

Plummeting Toronto Home Sales Reflect Trade, Political Uncertainty -- Market Talk

3 Apr 2025, 20:34 UTC

Top News

Trump's Tariffs Were Supposed to Boost the Dollar, But Here's Why the Opposite Happened -- Heard on the Street -- 2nd Update

3 Apr 2025, 20:23 UTC

Top News

Trump Tariffs Send Dow Industrials to 1600-Point Decline; Dollar Slumps -- WSJ

3 Apr 2025, 20:15 UTC

Acquisitions, Mergers, Takeovers

Blackstone Life Sciences And Anthos Therapeutics Announce Novartis Has Completed The Acquisition Of Anthos Therapeutics In A Deal Valued At Up To $3.1B, With $925M Paid Upfront >BX

3 Apr 2025, 19:55 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3 Apr 2025, 19:55 UTC

Market Talk

Dollar Weakens as Investors Seek Safety Elsewhere -- Market Talk

3 Apr 2025, 19:21 UTC

Market Talk

Oil Futures Slide on U.S. Tariffs, OPEC+ Output Plan -- Market Talk

3 Apr 2025, 19:15 UTC

Market Talk

U.S. Natural Gas Stays Focused on Weather, Storage -- Market Talk

3 Apr 2025, 18:45 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

3 Apr 2025, 18:45 UTC

Market Talk

Gold Drops In Tariff Fallout -- Market Talk

3 Apr 2025, 18:39 UTC

Market Talk

U.S. Tariffs Could Give Natural Gas Edge Over Solar -- Market Talk

3 Apr 2025, 18:38 UTC

Top News

Trump Tariffs Send Dow Industrials to 1400-Point Decline; Dollar Slumps -- WSJ

3 Apr 2025, 18:30 UTC

Top News

Auto Industry Braces for Major Pain From Trump's Tariffs -- Analysis

3 Apr 2025, 18:20 UTC

Market Talk

Uncertainty Still Roils Companies in Tariff Saga -- Market Talk

3 Apr 2025, 18:18 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

3 Apr 2025, 18:17 UTC

Market Talk

U.S. Workers Can't Match International Labor as Companies Consider Moving Supply Chains -- Market Talk

3 Apr 2025, 18:04 UTC

Market Talk

US Sees More Job Openings in Construction, Transportation -- Market Talk

3 Apr 2025, 17:55 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

Peer Comparison

Price change

Blueprint Medicines Corp Forecast

Price Target

By TipRanks

44.43% upside

12 Months Forecast

Average 130 USD  44.43%

High 155 USD

Low 100 USD

Based on 18 Wall Street analysts offering 12 month price targets forBlueprint Medicines Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

18 ratings

14

Buy

4

Hold

0

Sell

Technical Score

By Trading Central

88.53 / 93.08Support & Resistance

Short Term

Bearish Evidence

Intermediate Term

Weak Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

346 / 386 Healthcare

News Sentiment

Bearish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Blueprint Medicines Corp

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.